VivoSeq
Dermatology

Ichthyosis

10

Pipeline Programs↗

1

Active Trials↗

9

Companies Involved↗

Ichthyosis is an early-stage landscape with 10 programs across 9 companies. The most active players are Johnson & Johnson, Vanda Pharmaceuticals, Mayne Pharma International Pty Ltd. 2 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

78/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1V

Vanda Pharmaceuticals

1 program

Phase 2M

Mayne Pharma International Pty Ltd

1 program

Phase 2P

Patagonia Pharmaceuticals, LLC

1 program

Phase 2T

Timber Pharmaceuticals Inc.

1 program

Phase 3C

Cellegy Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

64%

Small molecule

7 of 11 classified programs — the dominant modality here.

36%ALL OTHERSMonoclonal antibody436%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

12

clinical trials

Completed7 · 58%
Terminated2 · 17%
Unknown status2 · 17%
Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

Efficacy of Injectable Gentamicin in Hereditary Ichthyosis
Not yet recruiting·UUniversity Hospital, Toulouse·Phase 2·NCT06362447·26 enrolled
A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis
Completed·TTimber Pharmaceuticals Inc.·Phase 2·NCT04154293·34 enrolled
A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris
Completed·CCrown Laboratories, Inc.·Phase 2·NCT03173547·80 enrolled
Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis
Completed·CCellegy Pharmaceuticals·Phase 3·NCT00004690·90 enrolled
The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
Completed·TTimber Pharmaceuticals Inc.·Phase 3·NCT05295732·153 enrolled
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Completed·AAldeyra Therapeutics, Inc.·Phase 2·NCT02402309·12 enrolled
A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Completed·PPatagonia Pharmaceuticals, LLC·Phase 2·NCT02864082·19 enrolled
Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis
Completed·GSK logoGSK·Phase 2/3·NCT00282724·98 enrolled
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
Terminated·VVanda Pharmaceuticals·Phase 2·NCT04697056·5 enrolled
A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis
Terminated·MMayne Pharma International Pty Ltd·Phase 2·NCT03738800·65 enrolled
Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children
Unknown status·NNational Medical Research Center for Children's Health, Russian Federation·Phase 4·NCT04996485·50 enrolled
Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous
Unknown status·—·Phase 3·NCT01222000·8 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)